polski | english | login
Array|Array|Array|Array|Array|Array

DOI: 10.18544/PEDM-23.01.0071
Pediatr Endocrinol Diabetes Metab 2017;23,1:30-36

Topinambour – nutritional and medical properties of the Jerusalem artichoke (Helianthus tuberoses L.)

Michalina Horochowska, Elżbieta Kołeczek, Zygmunt Zdrojewicz, Jacek Jagiełło, Karolina Pawlus

Key words

Helianthus tuberosus L., inulin, diabetes mellitus, prebiotic, breast cancer

Abstract

Topinambour (Helianthus tuberosus L.), also known as the Jerusalem artichoke is a plant, which origins from North America. In XVII century it was brought to the Europe. For ages it was cultivated due to edible tuber and its healing properties.The aim of the article is to present medical properties and application of topinmbour in patient’s diet. Many studies were performed on animals to specify medical properties of topinambour. Results show, that topinambour lowers plasma glucose, total cholesterol and triglyceride levels. It is believed that these effects are caused by high level of inulin present it its tuber.Inulin effect on the human organism was assessed in many clinical studies. It is thought it has prebiotic features, lowers plasma glucose and intestinal pH level, which results in higher calcium bioavailability. Additionaly, it has a positive impact on the plasma lipid profile, acts as an immunomodulator, affecting digestive systems’ limfatic tissue. Due to its characteristics, it can be used in the diet of obese and type 2 diabetes mellitus patients.Recently, it was discovered that topinambour tuber secretion works as a cytotoxic agent contra breast cancer cells.


Article published in polish language



advanced search »

Article in databases

DOI: 10.18544/PEDM-23.01.0071
PUBMED: view

Similar articles

...

Growth hormone therapy in a girl with Turner syndrome and diabetes type ...

The impact of having siblings – analysis of “hygiene theory” of chronic ...

Sugar content in non-alcoholic beverages and dietary recemmendations for ...

Prevalence of chronic complications in patients with over 30-year histor ...

Pediatric Endocrinology Diabetes and Metabolism

2018; 24, 1: 1-51
2017; 23, 4: 169-222
2017; 23, 3: 117-168
2017; 23, 2: 59-116
2017; 23, 1: 1-58
2016; 22, 4: 133-180
2016; 22, 3: 81-132
2016; 22, 2: 43-79
2016; 22, 1: 1-42
2015; 21, 4: 149-191
2015; 21, 3: 97-148
2015; 21, 2: 51-96
2015; 21, 1: 1-50
2014; 20, 4: 131-182
2014; 20, 3: 83-130
2014; 20, 2: 35-82